BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alere Announces Second Quarter 2010 Results


7/28/2010 11:39:49 AM

WALTHAM, Mass., July 28 /PRNewswire-FirstCall/ -- Alere Inc. (formerly known as Inverness Medical Innovations, Inc.) (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended June 30, 2010.

Financial results for the second quarter of 2010:

  • Net revenue of $523.0 million for the second quarter of 2010, compared to $438.7 million for the second quarter of 2009.
  • Recent professional diagnostics acquisitions contributed $62.5 million of incremental net revenue, compared to the second quarter of 2009.
  • North American influenza sales totaled $0.6 million for the second quarter of 2010, compared to $14.6 million for the second quarter of 2009.
  • GAAP net loss of $8.3 million attributable to common stockholders of Alere Inc. and respective net loss per common share of $0.10, compared to GAAP net loss of $1.2 million attributable to common stockholders of Alere Inc. and respective net loss per common share $0.01, for the second quarter of 2009.
  • Adjusted cash basis net income per diluted common share from continuing operations of $0.57, compared to adjusted cash basis net income per diluted common share from continuing operations of $0.57, for the second quarter of 2009.

The Company's GAAP results for the second quarter of 2010 include amortization of $74.1 million, $7.1 million of restructuring charges, $8.1 million of stock-based compensation expense, a $2.8 million charge associated with the write-up to fair market value of inventory acquired in connection with the acquisition of Standard Diagnostics, Inc., $2.0 million of acquisition-related costs recorded in accordance with ASC 805, Business Combinations, offset by $3.8 million of income recorded for fair value adjustments to acquisition-related contingent consideration obligations and a $1.3 million, net of tax, allocation of certain of the aforementioned charges to non-controlling stockholders. The Company's GAAP results for the second quarter of 2009 include amortization of $61.2 million, $4.9 million of restructuring charges, $6.6 million of stock-based compensation expense and $1.7 million of acquisition-related costs recorded in accordance with ASC 805, Business Combinations. These amounts, net of tax, have been excluded from the adjusted cash basis net income per diluted common share attributable to Alere Inc. for the respective quarters.

A detailed reconciliation of the Company's adjusted cash basis net income, which is a non-GAAP financial measure, to net income under GAAP, as well as a discussion regarding this non-GAAP financial measure, is included in the schedules to this press release.

The Company will host a conference call beginning at 10:00 a.m. (Eastern Time) today, July 28, 2010, to discuss these results as well as other corporate matters. During the conference call, the Company may answer questions concerning business and financial developments and trends and other business and financial matters. The Company's responses to these questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been previously disclosed.

The conference call may be accessed by dialing 706-679-1656 (domestic and international), an access code is not required, or via a link on the Alere website at www.alere.com/ic. It is also available via link at http://event.meetingstream.com/r.htm?e=228683&s=1&k=0E445AC7F725CFFA3E6F855A0C7A7BFD. An archive of the call will be available from the same link approximately two hours after the conclusion of the live call and will be accessible for 60 days. Additionally, reconciliations to non-GAAP financial measures not included in this press release that may be discussed during the call will also be available at the Alere website (www.alere.com/ic) under the Earnings Calls and Releases section shortly before the conference call begins and will continue to be available on this website.

For more information about Alere, please visit our website athttp://www.alere.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts.

Alere Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and

Reconciliation to Non-GAAP Adjusted Cash Basis Amounts

(in $000s, except per share amounts)































Three Months Ended June 30, 2010


Three Months Ended June 30, 2009








Non-GAAP






Non-GAAP








Adjusted






Adjusted






Non-GAAP


Cash




Non-GAAP


Cash




GAAP


Adjustments


Basis (a)


GAAP


Adjustments


Basis (a)
















Net product sales and services revenue

$ 516,880


$ -


$ 516,880


$ 434,972


$ -


$ 434,972


License and royalty revenue

6,080


-


6,080


3,680


-


3,680



Net revenue

522,960


-


522,960


438,652


-


438,652


Cost of net revenue

250,962


(21,359)

(b) (c) (d) (e)

229,603


200,756


(12,228)

(b) (c) (d)

188,528



Gross profit

271,998


21,359


293,357


237,896


12,228


250,124



Gross margin

52%




56%


54%




57%
















Operating expenses:














Research and development

32,760


(3,002)

(b) (c) (d)

29,758


26,039


(2,911)

(b) (c) (d)

23,128



Selling, general and administrative

217,180


(64,820)

(b) (c) (d) (f) (g)

152,360


184,587


(57,024)

(b) (c) (d) (f)

127,563



Total operating expenses

249,940


(67,822)


182,118


210,626


(59,935)


150,691



Operating income

22,058


89,181


111,239


27,270


72,163


99,433


Interest and other income (expense), net

(29,494)


265

(c) (f)

(29,229)


(21,096)




Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES